Overview

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Status:
Not yet recruiting

Trial end date:
2027-02-28

Target enrollment:

Participant gender:

Summary

This is a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. This study will collect clinical and cardiovascular risk factor data on patients ages 18 and older who are receiving relugolix or leuprolide acetate for their prostate cancer or as adjunct to radiation therapy with a treatment plan to be on androgen deprivation therapy (ADT) for at least one year.

Phase:

Phase 3

Details

Lead Sponsor:

Myovant Sciences GmbH

Treatments:

Leuprolide
Relugolix